Roche's CT-388 trials reveal a staggering 75% of high-dose injectable users experienced vomiting, sparking investor concern amid the competitive weight loss drug market.
A Roche representative noted, 'The safety and tolerability profile was consistent with other incretin-based therapies...typically improves with slower titrations over time.'
Despite Roche's reassurances, it's clear that nausea and vomiting risks in their drug align with other GLP-1 drugs, which also list similar side effects.
Current market leaders like Ozempic and Mounjaro have nausea as a common side effect, mirroring the results Roche found with CT-388.
Collection
[
|
...
]